MHRA – Page 195 – Pharma.Tips

Edge Lifting after adhesive change: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Edge Lifting Issues Post-Adhesive Change In pharmaceutical manufacturing, particularly within transdermal drug delivery systems, the integrity of adhesive bonds is critical. A common issue…

Dose Delivery Variability in transdermal patch manufacturing: inspection-ready documentation pack

Addressing Dose Delivery Variability in the Manufacturing of Transdermal Patches Dose delivery variability in transdermal patch manufacturing presents significant challenges, often manifesting as deviations or out-of-specification (OOS) results. This article…

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Addressing Pet Failures During PAI Readiness with Effective CAPA Implementation In pharmaceutical manufacturing, particularly with ophthalmic dosage forms, the readiness for a Pre-Approval Inspection (PAI) is critical. One widespread issue…

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Investigating Packaging Dry-Out Issues during Die-Cutting in Pharmaceutical Manufacturing In the dynamic environment of pharmaceutical manufacturing, particularly in the production of transdermal drug delivery systems, challenges such as packaging dry-out…

Assay Oos after adhesive change: GMP investigation plan and CAPA

Investigation Plan and CAPA for Assay OOS Following Adhesive Change Investigating Out-of-Specification (OOS) assay results after an adhesive change presents a critical challenge in pharmaceutical manufacturing. Such deviations can signify…

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

GMP Investigation Plan and CAPA for Ivpt Failures in Transdermal Patch Manufacturing In the pharmaceutical industry, ensuring consistent product quality is paramount, especially in the manufacturing of transdermal patches. An…

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Investigating Particulate Matter OOS for Multi-Dose Products: Effective Sampling, Filtration, and Environmental Controls Particulate matter contamination in multi-dose pharmaceutical products, particularly ophthalmic formulations, can pose significant challenges to manufacturers. The…

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

Examining Ccit Failure During Terminal Sterilization: An In-Depth Investigation Narrative Ccit failure during terminal sterilization poses significant challenges within pharmaceutical manufacturing, potentially leading to batch rejections and regulatory scrutiny. Understanding…

Tag: MHRA

Edge Lifting after adhesive change: GMP investigation plan and CAPA

Dose Delivery Variability in transdermal patch manufacturing: inspection-ready documentation pack

Pet Failure during PAI readiness: CAPA and effectiveness check plan

Packaging Dry-Out during die-cutting: inspection-ready documentation pack

Assay Oos after adhesive change: GMP investigation plan and CAPA

Ivpt Failure in transdermal patch manufacturing: GMP investigation plan and CAPA

Particulate Matter Oos for multi-dose products: sampling, filtration, and EM controls

Ccit Failure during terminal sterilization: FDA/MHRA investigation narrative and batch impact

Dose Delivery Variability during EU/UK market supply: inspection-ready documentation pack

Ph Drift during bulk hold: cleaning validation and worst-case selection

Dose Delivery Variability at accelerated stability: process parameter review and validation impact

E&L Failure after packaging change: sampling, filtration, and EM controls